Novo Nordisk A/S Common Stock (NY:NVO)

The choice isn't that hard.

Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? ↗

January 16, 2026

NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’ ↗

January 16, 2026

NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares? ↗

January 16, 2026

The United Kingdom’s Medicines and Healthcare products Regulatory Agency on Friday announced that it had approved a maximum dose of up to 7.2 milligrams a week for Novo’s Wegovy earlier this month.

AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly ↗

January 14, 2026

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

January 14, 2026

January 13, 2026

Novo Nordisk A/S (NYSE:NVO) shares are trading lower on Thursday after the company was hit with a lawsuit from compounding pharmacy Strive Specialties.

Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit ↗

January 15, 2026

Via Benzinga

Topics Lawsuit

Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation

January 15, 2026

In a bold move to solidify its dominance in the cardiometabolic market, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, that it has entered into a definitive agreement to acquire Ventyx...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive Specialties

Topics Intellectual Property

Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providers ↗

January 15, 2026

Via Benzinga

Topics Lawsuit

Slimmer Waistlines, Fatter Margins: Jefferies Says Airline Companies Will Profit From America’s Weight-Loss Boom ↗

January 14, 2026

Why Is HIMS Stock Slipping Premarket Today? ↗

January 12, 2026

Healthcare Sector Stages Resilient Rebound as Policy Clarity and GLP-1 Innovations Fuel Investor Optimism

January 14, 2026

The U.S. healthcare sector has entered 2026 on a remarkably strong footing, staging a decisive rebound after a tumultuous 2025. This resurgence is being driven by a rare alignment of legislative...

What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?

Topics Earnings Economy

Is It Time to Dump Your Shares of Eli Lilly? ↗

January 14, 2026

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Topics Intellectual Property

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns ↗

January 13, 2026

Via MarketBeat

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

January 13, 2026

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Topics Artificial Intelligence Economy Intellectual Property

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

January 13, 2026

Via PredictStreet

Topics Economy Intellectual Property

Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? ↗

January 13, 2026

Both companies now aim to win in the oral weight loss drug market.

The gap may be too hard to close in the next 12 months.

Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? ↗

January 13, 2026

The data provider's artificial intelligence-driven solutions are accelerating drug discovery.

Why Tempus AI Stock Rose Today ↗

January 12, 2026

Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution

Topics Artificial Intelligence

January 12, 2026

In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"...

Via TokenRing AI

Topics Artificial Intelligence

Anthropic Launches “Claude for Healthcare”: A Paradigm Shift in Medical AI Integration and HIPAA Security

January 12, 2026

On January 11, 2026, Anthropic officially unveiled Claude for Healthcare, a specialized suite of artificial intelligence tools designed to bridge the gap between frontier large language models and the...

Via TokenRing AI

Topics Artificial Intelligence

From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance

January 12, 2026

In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion...

The Convergence of Silicon and Science: Eli Lilly and Nvidia Unveil $1 Billion AI Co-Innovation Lab at JPM26

Topics Artificial Intelligence Economy Intellectual Property

January 12, 2026

In a move that signals the definitive arrival of the "AI-first" era for the pharmaceutical industry, Eli Lilly and Company (NYSE:LLY) and NVIDIA Corporation (NASDAQ:NVDA) announced a massive expansion...

What does the new year bring to investors?

Topics Artificial Intelligence

An Investor's Guide to 2026 ↗

January 12, 2026

Are you looking for investment opportunities in 2026?

Topics Artificial Intelligence Economy

Stocks to Love in 2026 ↗

January 11, 2026

It has strong momentum thanks to its current portfolio and several catalysts on the horizon.

Topics ETFs Initial Public Offering

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗

January 11, 2026

Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 09, 2026

In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...

The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance

January 09, 2026

As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company...